Prostate cancer risk variants are not associated with disease progression

Prostate

Volumn 72, Issue 1, 2012, Pages 30-39

  Szulkin, Robert ^a   Holmberg, Erik ^b   Stattin, Pär ^c   Xu, Jianfeng ^d   Zheng, Sigun ^d   Palmgren, Juni ^a,e   Grönberg, Henrik ^a   Wiklund, Fredrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d WAKE FOREST UNIVERSITY   (United States)

^e Stockholm University   (Sweden)

Author keywords

established risk variants; predictive performance; prostate cancer; prostate cancer progression

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 19Q; CHROMOSOME 22Q; CHROMOSOME 2P; CHROMOSOME 3P; CHROMOSOME 4Q; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME 9Q; CHROMOSOME XP; DISEASE ASSOCIATION; DISEASE COURSE; DISTANT METASTASIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 81855182171     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21403     Document Type: Article

References (40)

1. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J,. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102 (13): 950-958.
2. Schraudenbach P, Bermejo CE,. Management of the complications of radical prostatectomy. Curr Urol Rep 2007; 8 (3): 197-202.
3. Huang GJ, Sadetsky N, Penson DF,. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010; 183 (6): 2206-2212.
4. Klotz L,. Active surveillance for prostate cancer: A review. Curr Urol Rep 2010; 11 (3): 165-171.
5. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69 (6): 1095-1101.
6. Shariat SF, Karakiewicz PI, Margulis V, Kattan MW,. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008; 18 (3): 279-296.
7. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW,. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19 (5): 1193-1200.
8. Fradet Y,. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243-246.
9. Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW,. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011; 77 (3): 763.e1-6.
10. Hartman M, Lindstrom L, Dickman PW, Adami HO, Hall P, Czene K,. Is breast cancer prognosis inherited ? Breast Cancer Res 2007; 9 (3): R39.
11. Lindstrom LS, Hall P, Hartman M, Wiklund F, Gronberg H, Czene K,. Familial concordance in cancer survival: A Swedish population-based study. Lancet Oncol 2007; 8 (11): 1001-1006.
12. Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K,. Survival in bladder and renal cell cancers is familial. J Am Soc Nephrol 2008; 19 (5): 985-991.
13. Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P,. Concordance of survival in family members with prostate cancer. J Clin Oncol 2008; 26 (10): 1705-1709.
14. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, Isaacs WB, Xu J, Sun J,. Prostate cancer risk-associated variants reported from genome-wide association studies: Meta-analysis and their contribution to genetic variation. Prostate 2010; 70 (16): 1729-1738.
15. Varghese JS, Easton DF,. Genome-wide association studies in common cancers-What have we learnt ? Curr Opin Genet Dev 2010; 20 (3): 201-209.
16. Wiklund F,. Prostate cancer genomics: Can we distinguish between indolent and fatal disease using genetic markers ? Genome Med 2010; 2 (7): 45.
17. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W,. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009; 69 (11): 1195-1205.
18. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML,. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009; 15 (9): 3223-3230.
19. Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Gronberg H, Xu J,. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009; 18 (5): 1659-1662.
20. Barlow L, Westergren K, Holmberg L, Talback M,. The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 2009; 48 (1): 27-33.
21. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelson A, Bratt O, Damber JE, Hellstrom K, Hellstrom M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Tornblom M, Widmark A, Stattin P,. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41 (6): 456-477.
22. Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J,. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008; 180 (6): 2423-2429, discussion 2429-2430.
23. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K,. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38 (6): 652-658.
24. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D,. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006; 103 (38): 14068-14073.
25. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K,. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39 (5): 631-637.
26. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G,. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39 (5): 645-649.
27. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K,. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39 (8): 977-983.
28. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Gronberg H, Xu J, Carpten JD,. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99 (24): 1836-1844.
29. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ,. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40 (3): 310-315.
30. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Blondal T, Jakobsdottir M, Stacey SN, Kostic J, Kristinsson KT, Birgisdottir B, Ghosh S, Magnusdottir DN, Thorlacius S, Thorleifsson G, Zheng SL, Sun J, Chang BL, Elmore JB, Breyer JP, McReynolds KM, Bradley KM, Yaspan BL, Wiklund F, Stattin P, Lindstrom S, Adami HO, McDonnell SK, Schaid DJ, Cunningham JM, Wang L, Cerhan JR, St Sauver JL, Isaacs SD, Wiley KE, Partin AW, Walsh PC, Polo S, Ruiz-Echarri M, Navarrete S, Fuertes F, Saez B, Godino J, Weijerman PC, Swinkels DW, Aben KK, Witjes JA, Suarez BK, Helfand BT, Frigge ML, Kristjansson K, Ober C, Jonsson E, Einarsson GV, Xu J, Gronberg H, Smith JR, Thibodeau SN, Isaacs WB, Catalona WJ, Mayordomo JI, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K,. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40 (3): 281-283.
31. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF,. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40 (3): 316-321.
32. Huang SP, Huang LC, Ting WC, Chen LM, Chang TY, Lu TL, Lan YH, Liu CC, Yang WH, Lee HZ, Hsieh CJ, Bao BY,. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009; 18 (11): 3068-3074.
33. Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Hallden C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, Kirchhoff T, Offit K,. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010; 16 (10): 2819-2832.
34. Cheng I, Plummer S, Neslund-Dudas C, Klein EA, Casey G, Rybicki BA, Witte J,. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010; 19 (9): 2124-2132.
35. Lindstrom S, Adami HO, Balter KA, Xu J, Zheng SL, Stattin P, Gronberg H, Wiklund F,. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007; 13 (17): 5156-5161.
36. Lindstrom S, Adami HO, Balter K, Xu J, Zheng SL, Sun J, Stattin P, Gronberg H, Wiklund F,. Genetic variation in the upstream region of ERG and prostate cancer. Cancer Causes Control 2009; 20 (7): 1173-1180.
37. Stark JR, Wiklund F, Gronberg H, Schumacher F, Sinnott JA, Stampfer MJ, Mucci LA, Kraft P,. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009; 18 (6): 1859-1863.
38. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, Zheng SL, Xu J, Isaacs WB, Gronberg H, Breit SN, Wiklund FE,. Macrophage inhibitory cytokine 1: A new prognostic marker in prostate cancer. Clin Cancer Res 2009; 15 (21): 6658-6664.
39. Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL,. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate 2010; 70 (9): 1012-1019.
40. Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL,. CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010; 70 (10): 1094-1101.